TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 3302916
Drug: Delayed treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed treatment (48 to 56 hours)
Study: 3302916
Drug: Placebo treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo treatment (aspirin or acetaminophen)
Study: 22042749
Drug: Mometasone furoate
Normalized name: Mometasone Furoate
DrugBank: Mometasone furoate (DB14512)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Mometasone furoate nasal spray 400 µg twice daily
Study: 17569711
Drug: Methylphenidate (MPH)
DrugBank: Methylphenidate (DB00422)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methylphenidate (MPH) 0.60 mg/kg of body weight
Study: 10567626
Drug: Intravenous methylprednisolone
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous methylprednisolone (100 mg)
Study: 8918323
Drug: 200 IU/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 IU/kg once-daily dalteparin (group 1)
Study: 6749604
Drug: Branched-chain amino
Normalized name: Branched-chain amino acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Branched-chain amino acids (30 g) for longer periods (5 to 22 weeks)
Study: 26257021
Drug: Double-dose (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Double-dose (40 μg) recombinant hepatitis B vaccine at weeks 0, 4, and 24
Study: 26257021
Drug: Standard-dose (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-dose (20 μg) recombinant hepatitis B vaccine at weeks 0, 4, and 24
Study: 26257021
Drug: Double-dose (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Double-dose (40 μg) group
Study: 26257021
Drug: Standard-dose (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-dose (20 μg) group
Study: 24979519
Drug: Topical cyclosporine
Normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical cyclosporine A (CsA) 0.05% eyedrops
Study: 19397693
Drug: Fluvastatin/fenofibrate (80/200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluvastatin/fenofibrate (80/200 mg)
Study: 19397693
Drug: Simvastatin/ezetimibe (20/10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simvastatin/ezetimibe (20/10 mg)
Study: 2993687
Drug: Guar gum
Normalized name: Guar Gum
DrugBank: Guar gum (DB13446)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guar gum (5 g)
Study: 2451578
Drug: 10 ml
Normalized name: Vial Empty 10 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 ml dextran 70 in saline solution
Study: 2451578
Drug: 10 ml
Normalized name: Vial Empty 10 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 ml saline solution (control)
Study: 28898104
Drug: Ultrasound-guided barbotage
Normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrasound-guided barbotage combined with a subacromial corticosteroid injection (SAIC)
Study: 21428979
Drug: Calcipotriol cream
Normalized name: calcipotriol
DrugBank: Calcipotriol (DB02300)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcipotriol cream applied twice daily for 7 days before photoprovocation testing
Study: 21428979
Drug: Placebo cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo cream applied twice daily for 7 days before photoprovocation testing
Study: 9292632
Drug: Alprazolam (0.75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alprazolam (0.75 mg) administered on days 2 and 11
Study: 8385974
Drug: 0.01 mg
Normalized name: urea 0.01 MG/MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.01 mg kg‐1 intravenously (i.v.)
Study: 8385974
Drug: 0.1 mg
Normalized name: biotin 0.1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1 mg kg‐1 intravenously (i.v.)
Study: 8385974
Drug: 0.1 mg
Normalized name: biotin 0.1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1 mg kg‐1 orally (p.o.)
Study: 8385974
Drug: 0.03 mg
Normalized name: biotin 0.03 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.03 mg kg‐1 intravenously (i.v.)
Study: 8385974
Drug: 0.3 mg
Normalized name: biotin 0.3 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.3 mg kg‐1 intravenously (i.v.)
Study: 8385974
Drug: 0.1 mg
Normalized name: biotin 0.1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1 mg kg‐1 orally (p.o.) and 0.3 mg kg‐1 orally (p.o.)
Study: 3348613
Drug: Intravenous dosing
Normalized name: Metered Dose Inhaler
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous dosing
Study: 3519094
Drug: Controlled-release formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Controlled-release formulation of ketoprofen
Study: 3519094
Drug: Standard formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard formulation of ketoprofen
Study: 30635020
Drug: Sildenafil 25
Normalized name: sildenafil 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sildenafil 25 mg orally three times a day
Study: 29554173
Drug: Vaginal 10-μg
Normalized name: clotrimazole
DrugBank: Clotrimazole (DB00257)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vaginal 10-μg estradiol tablet (daily for 2 weeks, then twice weekly) plus placebo gel (3 times a week)
Study: 25605283
Drug: Clofazimine (Cfz)
Normalized name: Clofazimine
DrugBank: Clofazimine (DB00845)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clofazimine (Cfz) therapy group (n = 53)
Study: 23046862
Drug: Phaseolus vulgaris
Normalized name: PHASEOLUS VULGARIS WHOLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phaseolus vulgaris extract (PVE) 100 mg
Study: 16983393
Drug: Dutasteride (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dutasteride (0.5 mg daily for 2 years)
Study: 12826249
Drug: Concurrent paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Concurrent paclitaxel with external beam radiotherapy
Study: 12826249
Drug: Concurrent paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Concurrent paclitaxel and gemcitabine with RT followed by R115777
Study: 9355184
Drug: Argon green
Normalized name: argon
Approvals — FDA: no, EMA: no, PMDA: no
Description: Argon green laser treatment applied directly to the soft drusen in the temporal macula (Group 2)
Study: 9355184
Drug: Argon green
Normalized name: argon
Approvals — FDA: no, EMA: no, PMDA: no
Description: Argon green laser treatment applied directly to the soft drusen in the temporal macula (Group 1)
Study: 3016111
Drug: Intranasal recombinant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal recombinant interferon (rIFN; 2 X 10(6) IU/day)
Study: 30129268
Drug: Single-tufted toothbrush
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single-tufted toothbrush and conventional toothbrush combination (Group 3)
Study: 28028253
Drug: Intraperitoneal chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraperitoneal chemotherapy regimen of S‐1 combined with weekly intravenous and IP paclitaxel (PTX) administration, with a recommended dose of IP PTX being 20 mg/m2.
Study: 28028253
Drug: Intraperitoneal chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraperitoneal chemotherapy regimen of S‐1 combined with weekly intravenous and IP paclitaxel (PTX) administration for P1 gastric cancer.
Study: 28028253
Drug: Intraperitoneal chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraperitoneal chemotherapy (IP chemotherapy)
Study: 28028253
Drug: Intraperitoneal administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intraperitoneal administration of docetaxel
Study: 18087204
Drug: Maintenance antidepressant
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maintenance antidepressant (AD) medication
Study: 18087204
Drug: Intermittent use
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent use of antidepressants
Study: 1751434
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg mifepristone orally 36 h before operation
Study: 1751434
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg gemeprost vaginal pessary 3‐4 h preoperatively
Study: 25027701
Drug: Placebo (identical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (identical oral placebo)
Study: 23128033
Drug: Er:YAG laser
Approvals — FDA: no, EMA: no, PMDA: no
Description: Er:YAG laser treatment at 5.1 J/cm² (L(1))
Study: 23128033
Drug: Er:YAG laser
Approvals — FDA: no, EMA: no, PMDA: no
Description: Er:YAG laser treatment at 2.0 J/cm² (L(2))
Study: 11769363
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (hospital ward treatment)
Study: 12086760
Drug: Acarbose 100
Normalized name: acarbose 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acarbose 100 mg three times daily
Study: 7555508
Drug: Acarbose 200
Normalized name: Acarbose
DrugBank: Acarbose (DB00284)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acarbose 200 mg three times daily
Study: 7555508
Drug: Acarbose 300
Normalized name: Acarbose
DrugBank: Acarbose (DB00284)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acarbose 300 mg three times daily
Study: 7555508
Drug: Acarbose (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acarbose (all doses)
Study: 446319
Drug: Cimetidine 1.6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine 1.6 g/d
Study: 28241356
Drug: Placebo gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo gel for 1 year
Study: 24281841
Drug: Whey protein
Normalized name: Whey protein
DrugBank: Whey (DB18685)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whey protein (38 g protein)
Study: 20231228
Drug: Fentanyl (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fentanyl (2 microg/kg) and succinylcholine (2 mg/kg)
Study: 17664059
Drug: Infant formula
Normalized name: Infant formula
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infant formula with 0.6 g/100 mL of galacto-oligosaccharides (GOS) and long-chain fructo-oligosaccharides (lcFOS) in a ratio of 9/1
Study: 12475852
Drug: Diuretics and
Normalized name: Low-ceiling diuretics and potassium-sparing agents
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diuretics and colloids
Study: 31812702
Drug: Astodrimer 1%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Astodrimer 1% Gel
Study: 31812702
Drug: Placebo Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo Gel
Study: 27156803
Drug: Medical needling
Normalized name: NEEDLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical needling combined with non-cultured autologous skin cell suspension (NCASCS)
Study: 22956551
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg oral prednisolone daily for 4 weeks
Study: 16211697
Drug: Conjugated estrogens
Normalized name: Conjugated Estrogens
DrugBank: Conjugated estrogens (DB00286)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conjugated estrogens (CE) and medroxyprogesterone acetate (MPA) at a dose of 0.3/1.5 mg daily for 24 weeks
Study: 11846190
Drug: Meloxicam 7.5
Normalized name: meloxicam 7.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meloxicam 7.5 mg
Study: 10325662
Drug: Meloxicam 22.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meloxicam 22.5 mg
Study: 19380329
Drug: Diclofenac 150
Normalized name: diclofenac sodium 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diclofenac 150 mg
Study: 6679229
Drug: Oral drug
Normalized name: Drug Implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral drug therapy
Study: 1760998
Drug: Fish oil
Normalized name: Fish oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish oil supplementation (6 g daily for four weeks)
Study: 31593070
Drug: Conventional Oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional Oxygen Therapy (COT)
Study: 30089430
Drug: 10,000 therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10,000 therapeutic units (TU) of Dermatophagoides pteronyssinus allergoid preparation
Study: 30089430
Drug: 18,000 therapeutic
Approvals — FDA: no, EMA: no, PMDA: no
Description: 18,000 therapeutic units (TU) of Dermatophagoides pteronyssinus allergoid preparation
Study: 24663007
Drug: Herbst appliance
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Herbst appliance therapy
Study: 22324448
Drug: Synbiotic formulation
Normalized name: Synotic
DrugBank: Fluocinolone acetonide (DB00591)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Synbiotic formulation containing Lactobacillus paracasei B21060, arabinogalactan and xilooligosaccharides
Study: 17608790
Drug: AGT-6 genotype
Normalized name: PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 8
DrugBank: Streptococcus pneumoniae type 8 capsular polysaccharide antigen (DB10326)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AGT-6 genotype 'G/G' in men
Study: 17608790
Drug: AGT-6 genotype
Normalized name: PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 8
DrugBank: Streptococcus pneumoniae type 8 capsular polysaccharide antigen (DB10326)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AGT-6 genotype 'G/G' in women
Study: 2644753
Drug: Thoracic epidural
Normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thoracic epidural analgesia (TEA) with bupivacaine 50 mg via an epidural catheter, maintained by continuous infusion for 24 hours postoperatively.
Study: 186225
Drug: Renal arterial
Normalized name: Sus scrofa renal pelvis preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Renal arterial infusion of orthophosphate (Pi) in dogs
Study: 16562706
Drug: Daily health
Normalized name: Walgreens One Daily Healthy Weight Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily health education at DOTS centres
Study: 9013264
Drug: Dobutamine infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dobutamine infusion (3 micrograms/kg/min)
Study: 3877283
Drug: 0.05 ml/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.05 ml/kg Althesin
Study: 11719310
Drug: Nocturnal oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nocturnal oxygen therapy (NOT)
Study: 30407969
Drug: Auditory stimulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Auditory stimulation by a male nurse, recorded on MP3, administered twice a day for 10 days, repeated 3 to 4 times.
Study: 27391818
Drug: Structured multi‐component
Approvals — FDA: no, EMA: no, PMDA: no
Description: Structured multi‐component intervention (algorithm‐driven intervention using fixed‐dose combination antihypertensive treatment, subsidized FDC antihypertensive medication, motivational conversation, telephone follow‐ups)
Study: 12523588
Drug: Omeprazole 20
Normalized name: omeprazole 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole 20 mg b.i.d
Study: 1672578
Drug: vecuronium 0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: vecuronium 0.4 mg/kg
Study: 1672578
Drug: succinylcholine 2.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: succinylcholine 2.0 mg/kg
Study: 2905566
Drug: vecuronium 0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: vecuronium 0.1 mg/kg
Study: 1672578
Drug: vecuronium 0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: vecuronium 0.2 mg/kg
Study: 28337838
Drug: mavoglurant 50
Normalized name: Mavoglurant
DrugBank: Mavoglurant (DB13004)
Approvals — FDA: no, EMA: no, PMDA: no
Description: mavoglurant 50 mg
Study: 21360203
Drug: Combined HI-RT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined HI-RT and low-intensity blood flow restriction training (CB-RT, twice-weekly LI-BFR and once-weekly HI-RT)
Study: 19726310
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment with laparoscopy, endoscopic and digital subtraction angiography in addition to conventional treatment (group B)
Study: 21215151
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment (group A)
Study: 16780265
Drug: Betahistine treatment
Normalized name: betahistine
DrugBank: Betahistine (DB06698)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Betahistine treatment
Study: 16780265
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (different drugs)
Study: 15496643
Drug: desloratadine 5
Normalized name: desloratadine 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: desloratadine 5 mg plus fluoxetine 20 mg
Study: 15496643
Drug: fluoxetine 20
Normalized name: fluoxetine 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: fluoxetine 20 mg plus desloratadine 5 mg
Study: 9438485
Drug: QID dosing
Normalized name: MINOXIDIL 5 g in 100 mL / BIOTIN 5 g in 100 mL EXTRACORPOREAL AEROSOL, FOAM [QIDILA 5% Minoxidil Foam]
Approvals — FDA: no, EMA: no, PMDA: no
Description: QID dosing of inhaled corticosteroids
Study: 9438485
Drug: 8 AM
Normalized name: ACETYL HEXAPEPTIDE-8 AMIDE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 AM dosing of inhaled corticosteroids
Study: 8102538
Drug: Total parenteral
Normalized name: TPN - total parenteral nutrition
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total parenteral nutrition (n = 9)
Study: 23867808
Drug: QVA149 (110
Approvals — FDA: no, EMA: no, PMDA: no
Description: QVA149 (110 μg indacaterol/50 μg glycopyrronium)
Study: 24159259
Drug: IND+GLY (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: IND+GLY (150 μg indacaterol and 50 μg glycopyrronium)
Study: 16510466
Drug: Trimetazidine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trimetazidine (20 mg t.i.d.)
Study: 15107368
Drug: Exercise therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exercise therapy (active mobilisation)
Study: 15107368
Drug: Collar therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Collar therapy (cervical orthosis)
Study: 9735623
Drug: Mechanical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mechanical treatment with taping and orthoses
Study: 7986837
Drug: Spiral CT
Normalized name: Trichinella spiralis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spiral CT technique, CM dosage of 50 ml (30 ml at a flow rate of 2 ml/s and 20 ml at 0.7 ml/s)
Study: 31305423
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no CPAP therapy)
Study: 21355003
Drug: Trastuzumab monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trastuzumab monotherapy
Study: 16530506
Drug: Biofeedback (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biofeedback (5 weekly sessions)
Study: 16530506
Drug: Laxatives (polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Laxatives (polyethylene glycol 14.6‐29.2 g/day plus 5 weekly counseling sessions)
Study: 10657405
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (antithrombotic treatment)
Study: 9301505
Drug: Wheat bran
Normalized name: Wheat bran
DrugBank: Wheat bran (DB10685)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Wheat bran (25 g/day)
Study: 9301505
Drug: Oat bran
Normalized name: Oat bran
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oat bran (64 g/day)
Study: 9301505
Drug: Processed wheat
Normalized name: WHEAT
DrugBank: Wheat (DB10579)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Processed wheat bran (Kellogg's All Bran, 38 g/day)
Study: 3548611
Drug: Imipenem (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imipenem (500 mg t.i.d.)
Study: 3548611
Drug: Netilmicin plus
Normalized name: netilmicin
DrugBank: Netilmicin (DB00955)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Netilmicin plus Clindamycin (600 mg t.i.d.)
Study: 24178405
Drug: Rotational conjunctival
Normalized name: Sus scrofa conjunctiva preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rotational conjunctival flap with adjunctive subconjunctival 2.5 mg/0.1 ml bevacizumab injection (Group C)
Study: 20862715
Drug: Intravenous anisodamine
Normalized name: Anisodamine
DrugBank: Anisodamine (DB11785)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous anisodamine after surgery for 3 days
Study: 1814603
Drug: Ranitidine infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine infusion at 6.25 mg/hr
Study: 1814603
Drug: Ranitidine infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine infusion at 10.0 mg/hr
Study: 1814603
Drug: Ranitidine infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine infusion (6.25 mg/hr and 10.0 mg/hr)
Study: 1814603
Drug: Ranitidine infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine infusion
Study: 16135590
Drug: Outpatient treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Outpatient treatment (single intramuscular injection of cefoxitin and oral doxycycline)
Study: 16135590
Drug: Inpatient treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inpatient treatment (intravenous cefoxitin and doxycycline)
Study: 9346384
Drug: EPO treatment
Normalized name: epoetin alfa
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: EPO treatment (group II, n = 42)
Study: 1443808
Drug: Propofol (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol (2 mg.kg‐1 bolus, continuous infusion of 5 mg.kg‐1.h‐1) and alfentanil (10 micrograms.kg‐1 bolus, 5 micrograms.kg‐1 infusion)
Study: 1443808
Drug: Etomidate (0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etomidate (0.3 mg.kg‐1 bolus, continuous infusion of 1.5 mg.kg‐1.h‐1) and alfentanil (10 micrograms.kg‐1 bolus, 5 micrograms.kg‐1 infusion)
Study: 9751091
Drug: aspirin
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: aspirin
Study: 22515588
Drug: Targeted narrowband
Approvals — FDA: no, EMA: no, PMDA: no
Description: Targeted narrowband UVB phototherapy with psoralen gel (Group 2)
Study: 12676890
Drug: d-Amphetamine (0,
Approvals — FDA: no, EMA: no, PMDA: no
Description: d-Amphetamine (0, 2.5, 5, 10, and 15 mg)
Study: 1499947
Drug: Phentolamine (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phentolamine (5 mg/2 min followed by 500 micrograms/min)
Study: 1499947
Drug: Propranolol (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (5 mg/2 min followed by 80 micrograms/min)
Study: 25025852
Drug: Ghavoot (34
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ghavoot (34 g/dl) dissolved in 400 ml milk
Study: 25025852
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group received 400 ml milk
Study: 22075751
Drug: fenofibrate 160
Normalized name: fenofibrate 160 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: fenofibrate 160 mg/d for 3 weeks